Rayjean J. Hung

Rayjean J. Hung

Auto-generated profile, based on publicly available information

Rayjean J. Hung

Lunenfeld-Tanenbaum Research Institute, Sinai Health System, University of Toronto, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2018 in Nature
Verified
Journal Article
Closed access
PDF file
SSShu Yi Shen
Shu Yi Shen
RSRajat Singhania
Rajat Singhania
GFGordon Fehringer
Gordon Fehringer
ACAnkur Chakravarthy
Ankur Chakravarthy
MRMichael H. A. Roehrl
Michael H. A. Roehrl
DCDaniel D. De Carvalho
Daniel D. De Carvalho

12 June 2017 in Nature Genetics
Verified
Journal Article
Open access
PDF file
SCSpiroMeta Consortium
SpiroMeta Consortium
JMJames D McKay
James D McKay
RHRayjean J Hung
Rayjean J Hung
YHYounghun Han
Younghun Han
XZXuchen Zong
Xuchen Zong
CAChristopher I Amos
Christopher I Amos
Christopher Amos and colleagues perform genome-wide association analysis for lung cancer using cohorts genotyped on the OncoArray and combing these with existing data. They identify 18 loci, 10 of which are new, finding heterogeneity across the different lung cancer subtypes, and explore candidate genes through eQTL analysis in lung tissue. Although several lung cancer susceptibility loci have been identified, much of the heritability for lung cancer remains unexplained. Here 14,803 cases and 12,262 controls of European descent were genotyped on the OncoArray and combined with existing data for an aggregated genome-wide association study (GWAS) analysis of lung cancer in 29,266 cases and 56,450 controls. We identified 18 susceptibility loci achieving genome-wide significance, including 10 new loci. The new loci highlight the striking heterogeneity in genetic susceptibility across the histological subtypes of lung cancer, with four loci associated with lung cancer overall and six loci associated with lung adenocarcinoma. Gene expression quantitative trait locus (eQTL) analysis in 1,425 normal lung tissue samples highlights RNASET2, SECISBP2L and NRG1 as candidate genes. Other loci include genes such as a cholinergic nicotinic receptor, CHRNA2, and the telomere-related genes OFBC1 and RTEL1. Further exploration of the target genes will continue to provide new insights into the etiology of lung cancer.

1 May 2017 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
TCThe Telomeres Mendelian Randomization Collaboration
The Telomeres Mendelian Randomization Collaboration
PHPhilip C. Haycock
Philip C. Haycock
SBStephen Burgess
Stephen Burgess
ANAayah Nounu
Aayah Nounu
JZJie Zheng
Jie Zheng
GSGeorge Davey Smith
George Davey Smith
At the ends of chromosomes, telomeres are DNA-protein structures that protect the genome from damage, shorten progressively over time in most somatic tissues,1 and are proposed physiological markers of aging.2,3 Shorter leukocyte telomeres are correlated with older age, male sex, and other known risk factors for noncommunicable diseases4-6 and are generally associated with higher risk for cardiovascular diseases,7,8 type 2 diabetes,9 and nonvascular, non-neoplastic causes of mortality.8 Whether these associations are causal, however, is unknown. Telomere length has also been implicated in risk of cancer, but the direction and magnitude of the association is uncertain and contradictory across observational studies.10-14 The uncertainty reflects the considerable difficulty of designing observational studies of telomere length and cancer incidence that are sufficiently robust to reverse causation, confounding, and measurement error.

31 March 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DBDarren R Brenner
Darren R Brenner
JMJohn R McLaughlin
John R McLaughlin
RHRayjean J Hung
Rayjean J Hung
In order to review the epidemiologic evidence concerning previous lung diseases as risk factors for lung cancer, a meta-analysis and systematic review was conducted. Relevant studies were identified through MEDLINE searches. Using random effects models, summary effects of specific previous conditions were evaluated separately and combined. Stratified analyses were conducted based on smoking status, gender, control sources and continent. A previous history of COPD, chronic bronchitis or emphysema conferred relative risks (RR) of 2.22 (95% confidence interval (CI): 1.66, 2.97) (from 16 studies), 1.52 (95% CI: 1.25, 1.84) (from 23 studies) and 2.04 (95% CI: 1.72, 2.41) (from 20 studies), respectively, and for all these diseases combined 1.80 (95% CI: 1.60, 2.11) (from 39 studies). The RR of lung cancer for subjects with a previous history of pneumonia was 1.43 (95% CI: 1.22–1.68) (from 22 studies) and for subjects with a previous history of tuberculosis was 1.76 (95% CI = 1.49, 2.08), (from 30 studies). Effects were attenuated when restricting analysis to never smokers only for COPD/emphysema/chronic bronchitis (RR = 1.22, 0.97–1.53), however remained significant for pneumonia 1.36 (95% CI: 1.10, 1.69) (from 8 studies) and tuberculosis 1.90 (95% CI: 1.45, 2.50) (from 11 studies). Previous lung diseases are associated with an increased risk of lung cancer with the evidence among never smokers supporting a direct relationship between previous lung diseases and lung cancer.

8 February 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
AKAlison P Klein
Alison P Klein
BWBrian M. Wolpin
Brian M. Wolpin
HRHarvey A. Risch
Harvey A. Risch
RSRachael Z. Stolzenberg-Solomon
Rachael Z. Stolzenberg-Solomon
EMEvelina Mocci
Evelina Mocci
LALaufey T. Amundadottir
Laufey T. Amundadottir
In 2020, 146,063 deaths due to pancreatic cancer are estimated to occur in Europe and the United States combined. To identify common susceptibility alleles, we performed the largest pancreatic cancer GWAS to date, including 9040 patients and 12,496 controls of European ancestry from the Pancreatic Cancer Cohort Consortium (PanScan) and the Pancreatic Cancer Case-Control Consortium (PanC4). Here, we find significant evidence of a novel association at rs78417682 (7p12/TNS3, P = 4.35 × 10−8). Replication of 10 promising signals in up to 2737 patients and 4752 controls from the PANcreatic Disease ReseArch (PANDoRA) consortium yields new genome-wide significant loci: rs13303010 at 1p36.33 (NOC2L, P = 8.36 × 10−14), rs2941471 at 8q21.11 (HNF4G, P = 6.60 × 10−10), rs4795218 at 17q12 (HNF1B, P = 1.32 × 10−8), and rs1517037 at 18q21.32 (GRP, P = 3.28 × 10−8). rs78417682 is not statistically significantly associated with pancreatic cancer in PANDoRA. Expression quantitative trait locus analysis in three independent pancreatic data sets provides molecular support of NOC2L as a pancreatic cancer susceptibility gene.

17 October 2016 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CLCorina Lesseur
Corina Lesseur
BDBrenda Diergaarde
Brenda Diergaarde
AOAndrew F Olshan
Andrew F Olshan
VWVictor Wünsch-Filho
Victor Wünsch-Filho
ANAndrew R Ness
Andrew R Ness
PBPaul Brennan
Paul Brennan
Paul Brennan and colleagues perform genome-wide association analysis for oral cavity and pharyngeal cancer in trans-ancestry populations. They find seven new loci across different cancer subtypes, including a protective association in the HLA region that has a stronger effect in patients with human papillomavirus–positive cancers. We conducted a genome-wide association study of oral cavity and pharyngeal cancer in 6,034 cases and 6,585 controls from Europe, North America and South America. We detected eight significantly associated loci (P < 5 × 10−8), seven of which are new for these cancer sites. Oral and pharyngeal cancers combined were associated with loci at 6p21.32 (rs3828805, HLA-DQB1), 10q26.13 (rs201982221, LHPP) and 11p15.4 (rs1453414, OR52N2–TRIM5). Oral cancer was associated with two new regions, 2p23.3 (rs6547741, GPN1) and 9q34.12 (rs928674, LAMC3), and with known cancer-related loci—9p21.3 (rs8181047, CDKN2B-AS1) and 5p15.33 (rs10462706, CLPTM1L). Oropharyngeal cancer associations were limited to the human leukocyte antigen (HLA) region, and classical HLA allele imputation showed a protective association with the class II haplotype HLA-DRB1*1301–HLA-DQA1*0103–HLA-DQB1*0603 (odds ratio (OR) = 0.59, P = 2.7 × 10−9). Stratified analyses on a subgroup of oropharyngeal cases with information available on human papillomavirus (HPV) status indicated that this association was considerably stronger in HPV-positive (OR = 0.23, P = 1.6 × 10−6) than in HPV-negative (OR = 0.75, P = 0.16) cancers.